In conclusion, this study has demonstrated that a subset of GC and CRC exhibit elevated expression of PRKACA, which is associated with the overrepresentation of gene targets of multiple FDA-approved tyrosine kinase inhibitors and β-adrenergic signaling inhibitors. This evidence concerns the gene PRKACA and colorectal carcinoma.